Black Diamond Therapeutics
@blackdiamondtherapeutics.com
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing silevertinib, a potent, brain penetrant fourth-generation EGFR inhibitor for patients with non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
Black Diamond Therapeutics's Company Logos
Black Diamond Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#009FC2
Pacific Blue
0, 159, 194
191, 100, 38
100, 18, 0, 24
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#005366
Blue Stone
0, 83, 102
191, 100, 20
100, 19, 0, 60
About Black Diamond Therapeutics
Black Diamond Therapeutics is a biotechnology company developing targeted therapies for people with cancer. Its research focuses on non-small cell lung cancer (NSCLC) and glioblastoma (GBM), with the goal of addressing cancer mutations and resistance to treatment. The company’s MasterKey approach is designed to create therapies that can work across broad groups of genetically defined patients, overcome resistance, limit toxicities associated with effects on normal targets, and reach the brain to treat central nervous system disease.
Black Diamond’s pipeline includes silevertinib programs for NSCLC and GBM, as well as BDTX-4933 and BDTX-4876. The company also provides information about clinical trials and expanded access, and shares scientific presentations and publications about its work. Its stated mission is to help people living with cancer experience longer, healthier, and more active lives. To support this mission, it works with patient advocacy groups focused on NSCLC and GBM. The website also offers company and pipeline information, investor resources, news, and career opportunities.
Company type
Public Company
Year founded
2017
Company size
51-200 employees
Related Brands
Tags
Biopharmaceutical drug development
Precision oncology
Oral cancer therapies
NSCLC therapeutics
Glioblastoma therapeutics
